hepatocellular carcinoma
Conditions
Interventions
All included patients were treated with TACE, including conventional TACE (hereafter, cTACE) and drug-eluting bead TACE (hereafter, DEB-TACE), as described in Appendix S2. The objective response was d
Sponsors
Lishui Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (a) Patients with hepatocellular carcinoma who underwent initial transarterial chemoembolization (TACE) in Lishui Hospital of Zhejiang University (April 1, 2016, to December 31, 2022), the First Affiliated Hospital, Zhejiang University School of Medicine (January 1, 2018, to December 31, 2021), and the Hangzhou First People’s Hospital (January 1, 2017, to December 31, 2021); HCC was confirmed by imaging examinations evaluation. Biopsy was carried out if the nodule did not indicate typical features in medical images. (b) Contrast-enhanced magnetic resonance imaging (CE-MRI) was performed before and after TACE; (c) Relevant clinical information was available (i.e. demographics, preoperative hepatitis, serum alpha-fetoprotein (AFP) levels, and liver function tests).
Exclusion criteria
Exclusion criteria: (a) Underage patients; (b) Synchronous therapies during follow-up time, such as resection, and systemic chemotherapy; (c) With other malignancies and follow-up for less than 3 months after the operation. (d) Very small region of interest (ROI) or patients with poor MRI image quality.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the area under the receiver operating characteristics (ROC) curve (AUC); | — |
Secondary
| Measure | Time frame |
|---|---|
| accuracy;sensitivity;specificity; | — |
Countries
China
Contacts
Public ContactJi Jiansong
Lishui Hospital of Zhejiang University
Outcome results
None listed